| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000042220 |
| Receipt No. | R000047979 |
| Scientific Title | Evaluation study for intake of test food containing plant extract on effect in skin moisture |
| Date of disclosure of the study information | 2020/12/01 |
| Last modified on | 2021/01/22 (Ver. 3) |
| Basic information | ||
| Public title | Evaluation study for intake of test food containing plant extract on effect in skin moisture | |
| Acronym | Evaluation study for intake of test food containing plant extract on effect in skin moisture | |
| Scientific Title | Evaluation study for intake of test food containing plant extract on effect in skin moisture | |
| Scientific Title:Acronym | Evaluation study for intake of test food containing plant extract on effect in skin moisture | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate effect in skin moisture by taking the test food containing plant extract |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Transepidermal water loss (0-4-8-12w) |
| Key secondary outcomes | skin hydration
skin elasticity skin color difference Image analysis by VISIA AGEs reader Anti-Aging QOL Common Questionnaire blood test urine test body height body mass and BMI blood pressure, pulsation subjects'diary doctor's questions VAS questionnaire (0-4-8-12w) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake the active food for 12 weeks | |
| Interventions/Control_2 | Intake the placebo food for 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Japanese males and females aged 20 to 64 years old
2) Subjects who are concerned about their sagging skin 3) Subjects who are concerned about their skin wrinkles 4) Subjects who are concerned about their dry skin 5) Subjects who are conscious of skin symptoms caused by dry skin on their right cheeks, right necks, upper backs, right shins, right dorsums of feet or lower right inner arms every year from December to March. 6) Subjects who can refrain from drinking from the day before each measurement until the day of each measurement |
|||
| Key exclusion criteria | 1) Subjects who are taking medicines that can affect the test result
2) Subjects with chronic skin symptoms such as atopic dermatitis 3) Subjects who are using cosmetics containing hyaluronic acid, collagen, ceramide or vitamins or have used them within 1 month before the test 4) Subjects with histories of severe liver disorder, renal disorder or heart disease 5) Subjects with severe anemia 6) Subjects who are taking or plan to take medicines due to hay fever 7) Subjects who are currently attending dermatology 8) Subjects who are participating in other clinical trials or have participated in them within 3 months before the test 9) Subjects who are participating in other clinical trials 10) Subjects who are pregnant, breast-feeding or have possibility (hope) of pregnancy 11) Subjects who have sensitive skin or are allergic to the test product 12) Subjects who are allergic to the test product 13) Subjects with significant abnormality in skin conditions on their test sites 14) Subjects who have chronic illness and take drugs regularly 15) Subjects with asthma 16) Subjects who are taking medicines for skin such as L-cysteine and vitamins or have taken them within 1 month before the test |
|||
| Target sample size | 50 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Shiba Palace Clinic | ||||||
| Division name | Chair | ||||||
| Zip code | 105-0013 | ||||||
| Address | DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN | ||||||
| TEL | 03-5408-1590 | ||||||
| jimukyoku@mail.souken-r.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | SOUKEN Co., Ltd | ||||||
| Division name | Management Division | ||||||
| Zip code | 105-0013 | ||||||
| Address | DaiwaA Hamamatsucho Bldg. 3F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN | ||||||
| TEL | 03-5408-1555 | ||||||
| Homepage URL | |||||||
| k_masuda@mail.souken-r.com | |||||||
| Sponsor | |
| Institute | Shiba Palace Clinic |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ortho Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Shiba Palace Clinic Ethics Review Committee |
| Address | DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN |
| Tel | 03-5408-1599 |
| shiba_palace@s-palace-clinic.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 50 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047979 |